Bariatric surgery and T2DM improvement mechanisms: a mathematical model

BackgroundConsensus exists that several bariatric surgery procedures produce a rapid improvement of glucose homeostasis in obese diabetic patients, improvement apparently uncorrelated with the degree of eventual weight loss after surgery. Several hypotheses have been suggested to account for these results: among these, the anti-incretin, the ghrelin and the lower-intestinal dumping hypotheses have been discussed in the literature. Since no clear-cut experimental results are so far available to confirm or disprove any of these hypotheses, in the present work a mathematical model of the glucose-insulin-incretin system has been built, capable of expressing these three postulated mechanisms. The model has been populated with critically evaluated parameter values from the literature, and simulations under the three scenarios have been compared.ResultsThe modeling results seem to indicate that the suppression of ghrelin release is unlikely to determine major changes in short-term glucose control. The possible existence of an anti-incretin hormone would be supported if an experimental increase of GIP concentrations were evident post-surgery. Given that, on the contrary, collected evidence suggests that GIP concentrations decrease post-surgery, the lower-intestinal dumping hypothesis would seem to describe the mechanism most likely to produce the observed normalization of Type 2 Diabetes Mellitus (T2DM) after bariatric surgery.ConclusionsThe proposed model can help discriminate among competing hypotheses in a context where definitive data are not available and mechanisms are still not clear.

[1]  H. Neels,et al.  Reference Values for Plasma Dipeptidyl Peptidase IV Activity and Their Association with Other Laboratory Parameters , 2001, Clinical chemistry and laboratory medicine.

[2]  S. Shikora,et al.  Neuro‐modulation and bariatric surgery for type 2 diabetes mellitus , 2010, International journal of clinical practice. Supplement.

[3]  H. Hendriks,et al.  Ghrelin response to carbohydrate-enriched breakfast is related to insulin. , 2005, The American journal of clinical nutrition.

[4]  K. Cianflone,et al.  Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[5]  R. Gómez-Huelgas [Bariatric surgery versus conventional medical therapy for type 2 diabetes]. , 2012, Revista clinica espanola.

[6]  F. Reimann,et al.  Nutritional regulation of glucagon‐like peptide‐1 secretion , 2009, The Journal of physiology.

[7]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[8]  M. Suter,et al.  Effects of Gastric Bypass and Gastric Banding on Glucose Kinetics and Gut Hormone Release , 2008, Obesity.

[9]  N. Scopinaro,et al.  Biliopancreatic Diversion , 1998, World Journal of Surgery.

[10]  F. Rubino,et al.  The effect of bilio-pancreatic diversion on type 2 diabetes in patients with BMI <35 kg/m2 , 2009, Diabetologia.

[11]  I. Godsland,et al.  Evaluation of four mathematical models of glucose and insulin dynamics with analysis of effects of age and obesity. , 1992, The American journal of physiology.

[12]  N. Scopinaro,et al.  Restoration of Acute Insulin Response in T2DM Subjects 1 Month After Biliopancreatic Diversion , 2008, Obesity.

[13]  M. Nauck,et al.  Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes , 2006, Diabetologia.

[14]  Executive Summary: Standards of Medical Care in Diabetes—2011 , 2011, Diabetes Care.

[15]  J. Girard The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. , 2008, Diabetes & metabolism.

[16]  W. Malaisse,et al.  Changes in Glucagon-like Peptide-1 (GLP-1) Secretion after Biliopancreatic Diversion or Vertical Banded Gastroplasty in Obese Subjects , 2005, Obesity surgery.

[17]  D. D. de Luis,et al.  The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. , 2007, American journal of surgery.

[18]  C. Deacon,et al.  What do we know about the secretion and degradation of incretin hormones? , 2005, Regulatory Peptides.

[19]  M. Rickels,et al.  Narrative Review: Effect of Bariatric Surgery on Type 2 Diabetes Mellitus , 2009, Annals of Internal Medicine.

[20]  Karan P. Singh,et al.  Theoretical Biology and Medical Modelling , 2007 .

[21]  Elan L. Ohayon,et al.  A Mathematical Model of the Oral Glucose Tolerance Test Illustrating the Effects of the Incretins , 2007, Annals of Biomedical Engineering.

[22]  J. Després,et al.  Abdominal obesity and metabolic syndrome , 2006, Nature.

[23]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[24]  M. Tschöp,et al.  Ghrelin Suppresses Glucose-Stimulated Insulin Secretion and Deteriorates Glucose Tolerance in Healthy Humans , 2010, Diabetes.

[25]  M. Nakazato,et al.  Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. , 2000, Endocrinology.

[26]  M. Ferrone,et al.  Differential Effect of Weight Loss on Insulin Resistance in Surgically Treated Obese Patients. , 2006, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[27]  J. Meier The contribution of incretin hormones to the pathogenesis of type 2 diabetes. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[28]  Simon Hess,et al.  Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis. , 2011, Cell metabolism.

[29]  R. Tacchino,et al.  Normalization of Insulin Sensitivity in the Obese Patient after Stable Weight Reduction with Bilio-Pancreatic Diversion , 1994, Obesity surgery.

[30]  J. Holst,et al.  The incretin system and its role in type 2 diabetes mellitus , 2009, Molecular and Cellular Endocrinology.

[31]  D. Cummings Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery , 2009, International Journal of Obesity.

[32]  Francesco Rubino,et al.  Is Type 2 Diabetes an Operable Intestinal Disease? , 2008, Diabetes Care.

[33]  Thomas J. H. Chen,et al.  Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. , 1995, Pharmacogenetics.

[34]  G. Mingrone,et al.  Ultradian ghrelin pulsatility is disrupted in morbidly obese subjects after weight loss induced by malabsorptive bariatric surgery. , 2006, The American journal of clinical nutrition.

[35]  S. Bloom,et al.  Gut hormones and appetite control. , 2007, Gastroenterology.

[36]  N. Volkow,et al.  Decreased dopamine type 2 receptor availability after bariatric surgery: Preliminary findings , 2010, Brain Research.

[37]  J. Holst,et al.  GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine , 2003, Regulatory Peptides.

[38]  S. Salinari,et al.  First-Phase Insulin Secretion Restoration and Differential Response to Glucose Load Depending on the Route of Administration in Type 2 Diabetic Subjects After Bariatric Surgery , 2009, Diabetes Care.

[39]  V. Basevi Standards of Medical Care in Diabetes—2011 , 2011, Diabetes Care.

[40]  F. Rubino,et al.  Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of 2 cases. , 2007, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[41]  E. Ferrannini,et al.  Impact of Different Bariatric Surgical Procedures on Insulin Action and β-Cell Function in Type 2 Diabetes , 2009, Diabetes Care.

[42]  D. D’Alessio,et al.  Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1–Stimulated Postprandial Insulin Secretion in Humans , 2011, Diabetes.

[43]  B. Göke,et al.  Gastric emptying and release of incretin hormones after glucose ingestion in humans. , 1996, The Journal of clinical investigation.

[44]  Benjamin S. Aribisala,et al.  Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol , 2011, Diabetologia.

[45]  G. Mingrone Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[46]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[47]  J. Holst,et al.  Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion , 2009, Diabetologia.

[48]  M. S. Kirkman,et al.  Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011 .

[49]  C. Könner Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis , 2012 .

[50]  A. Mari,et al.  Mechanisms of Recovery From Type 2 Diabetes After Malabsorptive Bariatric Surgery , 2006, Diabetes.

[51]  J. Holst,et al.  Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. , 2004, Diabetes.

[52]  D. Zheng,et al.  Mechanism for improved insulin sensitivity after gastric bypass surgery. , 2008, The Journal of clinical endocrinology and metabolism.

[53]  E. Ghigo,et al.  Neuroendocrine and metabolic effects of acute ghrelin administration in human obesity. , 2003, The Journal of clinical endocrinology and metabolism.

[54]  M. Papotti,et al.  Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[55]  E. Verspohl Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. , 2009, Pharmacology & therapeutics.

[56]  J. Marescaux,et al.  Effect of Duodenal–Jejunal Exclusion in a Non-obese Animal Model of Type 2 Diabetes: A New Perspective for an Old Disease , 2004, Annals of surgery.

[57]  H. Kwon,et al.  Early Changes in Incretin Secretion After Laparoscopic Duodenal–Jejunal Bypass Surgery in Type 2 Diabetic Patients , 2010, Obesity surgery.

[58]  Thomas D. Giles,et al.  Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[59]  G. Dohm,et al.  A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? , 1998, Annals of surgery.

[60]  Yuxiang Sun,et al.  Central and Peripheral Roles of Ghrelin on Glucose Homeostasis , 2007, Neuroendocrinology.

[61]  J. Egan,et al.  Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. , 2006, American journal of physiology. Endocrinology and metabolism.

[62]  E. Dellinger,et al.  Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. , 2002, The New England journal of medicine.

[63]  T. Hansen,et al.  Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1 , 1995, The Lancet.

[64]  J. Teixeira,et al.  Do Incretins Play a Role in the Remission of Type 2 Diabetes after Gastric Bypass Surgery: What are the Evidence? , 2009, Obesity surgery.

[65]  San-yuan Hu,et al.  Ileal Transposition Controls Diabetes as Well as Modified Duodenal Jejunal Bypass With Better Lipid Lowering in a Nonobese Rat Model of Type II Diabetes by Increasing GLP-1 , 2008, Annals of surgery.

[66]  J. Teixeira,et al.  Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery , 2010, Journal of diabetes.

[67]  K. Blum,et al.  Neuro-Genetics of Reward Deficiency Syndrome (RDS) as the Root Cause of "Addiction Transfer": A New Phenomenon Common after Bariatric Surgery. , 2011, Journal of genetic syndromes & gene therapy.

[68]  J. Girard,et al.  Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. , 2008, Diabetes & metabolism.

[69]  D. Cummings,et al.  Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. , 2007, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[70]  R. Batterham,et al.  Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters , 2006, Annals of surgery.

[71]  R. Seeley,et al.  Bypassing the duodenum does not improve insulin resistance associated with diet-induced obesity in rodents , 2010 .

[72]  J. Teixeira,et al.  Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. , 2008, The Journal of clinical endocrinology and metabolism.

[73]  W. Pories,et al.  Who Would Have Thought It? An Operation Proves to Be the Most Effective Therapy for Adult‐Onset Diabetes Mellitus , 1995, Annals of surgery.

[74]  J. Marescaux,et al.  The Mechanism of Diabetes Control After Gastrointestinal Bypass Surgery Reveals a Role of the Proximal Small Intestine in the Pathophysiology of Type 2 Diabetes , 2006, Annals of surgery.

[75]  A. Baron,et al.  Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. , 2005, The New England journal of medicine.

[76]  J. Holst,et al.  Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. , 2003, The Journal of clinical endocrinology and metabolism.

[77]  J. Holst The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.

[78]  B. Wolfe,et al.  Bariatric surgery: a review of procedures and outcomes. , 2007, Gastroenterology.

[79]  D. Drucker The role of gut hormones in glucose homeostasis. , 2007, The Journal of clinical investigation.

[80]  J. Holst,et al.  Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. , 2007, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[81]  M. Gagner,et al.  The Early Effect of the Roux-en-Y Gastric Bypass on Hormones Involved in Body Weight Regulation and Glucose Metabolism , 2004, Annals of surgery.

[82]  B. Bistrian,et al.  Rapid Communication Circulating Ghrelin Concentrations Are Lowered by Intravenous Glucose or Hyperinsulinemic Euglycemic Conditions in Rodents , 2022 .

[83]  M. Berger,et al.  Effects of fish oil on the neuro-endocrine responses to an endotoxin challenge in healthy volunteers. , 2007, Clinical nutrition.

[84]  M. Schambelan,et al.  Improvement in Peripheral Glucose Uptake After Gastric Bypass Surgery Is Observed Only After Substantial Weight Loss Has Occurred and Correlates with the Magnitude of Weight Lost , 2009, Journal of Gastrointestinal Surgery.

[85]  G. Mingrone,et al.  Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. , 2009, Diabetes & metabolism.

[86]  J. Marescaux,et al.  The role of the small bowel in the regulation of circulating ghrelin levels and food intake in the obese Zucker rat. , 2005, Endocrinology.

[87]  J. Holst,et al.  Incretins, insulin secretion and Type 2 diabetes mellitus , 2004, Diabetologia.

[88]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[89]  Mats O Karlsson,et al.  An Integrated Glucose‐Insulin Model to Describe Oral Glucose Tolerance Test Data in Healthy Volunteers , 2010, Journal of clinical pharmacology.